What is the latest domestic selling price of Teclistamab-cqyv?

Teritusumab (Teclistamab-cqyv) is an innovative immunotherapy drug developed to treat relapsed or refractory multiple myeloma (RRMM). This is a bispecific T-cell engaging antibody that targets both CD3 and BCMA molecules at the same time, thereby activating T cells to accurately attack myeloma cells. The drug has been approved for marketing in Europe and the United States and is gradually being used clinically.

As for the selling price of teritusumab in China, its pricing is not yet fully transparent as the drug has not yet fully entered the domestic market. Existing information shows that the generic drug Teritusumab has been applied for and approved for marketing in China, but it has not yet been fully entered into the drug catalogs of major hospitals, nor has it entered the medical insurance catalog, which means that in the short term, patients will still mainly obtain the drug through overseas channels or individual import channels.

At present, the price of teritusumab in overseas markets is relatively high, and the price is greatly affected by exchange rates and packaging specifications. Taking Europe as an example, the price of a small 30mg/3ml package is approximately RMB 10,000 to 15,000, while a large package of 153mg/1.7ml may cost RMB 50,000 or more per box. In the United States, the market price of the drug is higher, and the cost of each standard treatment cycle may be as high as hundreds of thousands of yuan. It is worth noting that the above price is only the cost of the drug itself, and does not include possible shipping costs, taxes, etc.

There are currently no generic versions of teritusumab available on the market, and no approved biosimilars have been found globally, meaning patients can only rely on the original version for treatment. This undoubtedly constitutes a significant burden for patients under greater financial pressure.

Therefore, the full domestic launch and inclusion of teritusumab in medical insurance will become an important node in determining its accessibility. Patients pay close attention to the updates of the State Food and Drug Administration to understand the official circulation time of the drug in China and medical insurance coverage information, so that they can obtain timely and effective treatment when needed.

Reference materials:https://www.tecvayli.com/